Skip to main content

Free Content Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers

Download Article:
(PDF 91.078125 kb)
OBJECTIVE: To assess the bioavailability of rifampicin (RMP) in three brands of combination formulations of anti-tuberculosis drugs.

DESIGN: A three-way double-blind, cross-over bioavailability study of RMP and isoniazid (INH), consisting of a comparison of a two-drug combination of tablets of RMP and INH each separately (reference brand R) and a tablet of RMP + INH (brand N), and a capsule of RMP + INH (brand L) was carried out in 12 healthy male volunteers. Coded plasma samples were analysed for levels of RMP as well as INH and acetylisoniazid (ACINH) by two high performance liquid chromatography (HPLC) methods.

RESULTS: The mean values of RMP in brand N (Cmax 6.49 ± 0.52 μg/mL, Tmax 2.33 ± 0.18 h, AUC(0–24) 39.83 ± 3.44 μg/mL.h) were comparable with those obtained with brand R (Cmax 5.22 ± 0.59 μg/mL, Tmax 2.50 ± 0.12 h, AUC(0–24) 33.33 ± 3.47 μg/mL.h). The mean values of RMP in brand L (Cmax 3.05 ± 0.52 μg/mL, Tmax 3.79 ± 0.57 h and AUC(0–24) 21.78 ± 3.67 μg/mL.h) were significantly different from those in brand R. Nevertheless, all of the pharmacokinetic parameters obtained for INH and ACINH in all three brands were comparable.

CONCLUSION: Using brand R as a comparison, brand N was bioequivalent and brand L was not bioequivalent.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: bioavailability; multidrug combinations; rifampicin

Document Type: Regular Paper

Affiliations: 1: Department of Clinical Pharmacology, LTM Medical College, Sion Hospital, Mumbai, India 2: Novartis India Limited, Medical Department, Khetan Bhavan, Churchgate, Mumbai, India

Publication date: 1999-07-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more